EUR/USD at 52 week high
Asia-Pacific stocks lacked firm direction as momentum faded from the record-setting performance on Wall St, where the S&P 500 and Nasdaq printed fresh all-time highs
EUR/GBP: testing the 200-MA
Information is not investment advice
Key indicators
Performance in 2020: +3.8%
Last day range: 0.8752 – 0.8780
52-week range: 0.8280 – 0.9326
Observing the limits
While the UK’s response to virus with precautionary measures has been minimal so far, the British businesses do suffer from the coronavirus global consequences. And although Europe faces more significant economic damage altogether, its currency doesn’t seem to lose the battle against the British pound this time. In the middle of February, EUR/GBP came to observe the strategic 2-year low of 0.8280 but chose not to cross it. Since then, it has been rising and currently trades at 0.8775. That’s where it tests the 200-day Moving Average, being above it for the third day in a row. The Awesome Oscillator hints that a correction downwards is possible before the next move upwards. In the latter, psychological resistance levels at 0.8800, 0.8900 and 0.9000 may be the possible targets in the mid-term.
Technical levels
Resistance 0.8800
Support 0.8640
Similar
USD bulls try to resist
Fed's Powell said a slowing recovery and a surging pandemic meant the US was entering a "challenging" few months, with the potential deployment of a vaccine still facing hurdles.
Cable inches towards key resistance near 1.3400
The progress on the COVID-19 vaccines and hopes of a swift economic rebound next year added to the optimistic sentiment in the market.
Popular
Gold: bullish forecasts
XAU/USD is eyeing $1 850. Will it be able to reach it?
EUR/USD at 52 week high
Asia-Pacific stocks lacked firm direction as momentum faded from the record-setting performance on Wall St, where the S&P 500 and Nasdaq printed fresh all-time highs
USD bulls try to resist
Fed's Powell said a slowing recovery and a surging pandemic meant the US was entering a "challenging" few months, with the potential deployment of a vaccine still facing hurdles.
Choose your payment system
